| Recruiting | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic D NCT07087912 | University of Sao Paulo General Hospital | Phase 4 |
| Recruiting | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110 | Essen Biotech | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) NCT06294236 | Sana Biotechnology | Phase 1 |
| Terminated | PR3-AAV Resilient Remission or PRRR NCT05376319 | Mayo Clinic | Phase 2 |
| Completed | Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. NCT05703802 | University Hospital Muenster | — |
| Completed | Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator NCT05716334 | McGill University Health Centre/Research Institute of the McGill University Health Centre | — |
| Unknown | Hydroxychloroquine in ANCA Vasculitis Evaluation NCT04316494 | Guy's and St Thomas' NHS Foundation Trust | Phase 4 |
| Completed | PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis NCT04280601 | Christian Pagnoux | N/A |
| Completed | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis NCT03482479 | University of Pennsylvania | Phase 2 |
| Completed | Journey of Patients With Vasculitis From First Symptom to Diagnosis NCT03410290 | University of Pennsylvania | — |
| Recruiting | VCRC Tissue Repository NCT02967068 | University of Pennsylvania | — |
| Terminated | Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis NCT02474888 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | Impact of Vasculitis on Employment and Income NCT02476292 | University of South Florida | — |
| Withdrawn | BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During NCT01598857 | Anthera Pharmaceuticals | Phase 2 |
| Unknown | Low-dose Glucocorticoid Vasculitis Induction Study NCT02198248 | Chiba University | Phase 4 |
| Completed | Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis NCT02169219 | Massachusetts General Hospital | Phase 4 |
| Completed | VCRC Patient Contact Registry Patient-Reported Data Validation Study NCT02190942 | University of South Florida | — |
| Unknown | Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis NCT02126098 | Peking Union Medical College Hospital | — |
| Completed | Rituximab Vasculitis Maintenance Study NCT01697267 | Cambridge University Hospitals NHS Foundation Trust | Phase 3 |
| Unknown | Pediatric Vasculitis Initiative NCT02006134 | University of British Columbia | — |
| Completed | Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis NCT01731561 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Unknown | PRO Development for ANCA Associated Vasculitis NCT01729624 | University of Oxford | — |
| Completed | An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With NCT01613599 | Genentech, Inc. | — |
| Terminated | Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study NCT01586858 | Johns Hopkins University | — |
| Completed | Educational Needs of Patients With Systemic Vasculitis NCT02190929 | University of South Florida | — |
| Completed | Vasculitis Illness Perception (VIP) Study NCT02190916 | University of South Florida | — |
| Completed | Reproductive Health in Men and Women With Vasculitis NCT02176070 | University of South Florida | — |
| Unknown | Alemtuzumab for ANCA Associated Refractory Vasculitis NCT01405807 | Cambridge University Hospitals NHS Foundation Trust | Phase 4 |
| Unknown | American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification NCT01066208 | University of Oxford | — |
| Recruiting | One-Time DNA Study for Vasculitis NCT01241305 | University of Pennsylvania | — |
| Completed | Efficacy Study of Two Treatments in the Remission of Vasculitis NCT00748644 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis NCT00315393 | University of Pennsylvania | — |
| Completed | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years NCT00307671 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis NCT00104299 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 / Phase 3 |
| Completed | RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides NCT00307593 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Anti-Cytokine Therapy for Vasculitis NCT00753103 | University Hospital Birmingham NHS Foundation Trust | Phase 2 |
| Completed | CellCept in p-ANCA Vasculitis NCT00405860 | Mayo Clinic | Phase 1 |
| Completed | Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides NCT00430105 | Cambridge University Hospitals NHS Foundation Trust | Phase 2 / Phase 3 |
| Unknown | CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors NCT00400075 | Hospices Civils de Lyon | Phase 4 |
| Terminated | Plasma Exchange for Renal Vasculitis NCT01408836 | Cambridge University Hospitals NHS Foundation Trust | Phase 2 / Phase 3 |
| Unknown | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides NCT00751517 | University of Parma | Phase 2 |